TO FIND OUT MORE VISIT OUR EXHIBITION STALL OR WATCH DR McCLUNAN'S PRESENTATION AT WOC2020

iPortVR

 

The iPortVR is a vitreoretinal oculosubarachnoid glaucoma device (VOGD), inserted via the ab-interno pathway. The device creates a micro shunt communication between the ocular posterior chamber and the retrolaminar subarachnoid space.


Through oculosubarachnoid shunting, the iPortVR aims to offer the same highly effective IOP control demonstrated by the OptiShunt. By making use of ab-interno implantation, the iPortVR is designed to be fast, simple and minimally invasive to insert.


The iPortVR is the first ever glaucoma device designed for use during vitreoretinal(VR) surgery. VR surgery is commonly associated with glaucoma. iValve technology built into the design makes the iPortVR compatible for use with all VR tamponading agents.


Pre-clinical testing of the iPortVR is currently underway. The Glaucoma treatment by Oculosubarachnoid Vitreoretinal Implant Device (GOVID) study is the iPortVR early feasibility study planned to kick off in 2021.

Glaucoma remains a leading cause of blindness worldwide, affecting over 70 million people

Contact

Dr Daemon McClunan, Founder
email: daemon@liqidmedical.com

mobile: +27 (0)84 604 7600

location: Cape Town, South Africa

You Tube icon white edited

© 2017 Copyright reserved. Online Solutions by CassandraGroenewald.com